Slide 1: Conference Call Nine-Month 2016 Results
Conference Call Nine-Month 2016 Results Joachim Kreuzburg, CEO | October 24, 2016
Slide 2: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group and the Sartorius Stedim Biotech Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarante
Slide 3: Agenda
Agenda 01 Sartorius Group 9M 2016 Results | FY 2016 Guidance 02 Sartorius Stedim Biotech Group 9M 2016 Results | FY 2016 Guidance 03 Questions & Answers
Slide 4: 9M 2016 Highlights
9M 2016 Highlights Continued double-digit growth in sales revenue and earnings Strong performance of Bioprocess Solutions division Sustained positive business development of Lab Products & Services Integration of recent acquisitions well on track FY 2016 sales & earnings guidance confirmed 4
Slide 5: Dynamic Growth Across All Lines
Dynamic Growth Across All Lines Sartorius Group in millions of € unless otherwise specified 9M 2015 9M 2016 in % in % cc 1 Sales revenue 830.3 965.1 +16.2 +17.9 Order intake 856.6 988.2 +15.4 +17.0 Underlying EBITDA2 193.8 241.4 +24.6 Underlying EBITDA2 margin in % 23.3 25.0 +1.7 pp Underlying EPS 3
Slide 6: All Regions Post Double-Digit Gains
All Regions Post Double-Digit Gains Americas EMEA Asia | Pacific Sales by Region € in millions € in millions € in millions in % 427.1 EMEA ~ 44% 379.0 331.4 278.7 Americas ~ 34% 206.6 172.6 € 965.1m Asia | Pacific ~ 22% 9M 15 9M 16 9M 15 9M 16 9M 15 9M 16 +20.3% +14.6% +21.3% Acc. to customers‘ loca
Slide 7: BPS: Strong Performance in Line with Expectations
BPS: Strong Performance in Line with Expectations Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +19.7% cc +21.9% cc +27.7% +18.1% +20.3% 752.5 726.7 202.6 637.2 604.3 158.7 27.9% 26.3% 9M 15 9M 16 9M 15 9M 16 9M 15 9M 16 Continued dynamic market en
Slide 8: LPS: Ongoing Positive Business Development
LPS: Ongoing Positive Business Development Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +9.1% cc +7.1% cc +10.4% +7.3% +5.5% 235.6 226.0 238.4 38.7 219.5 35.1 16.2% 15.5% 9M 15 9M 16 9M 15 9M 16 9M 15 9M 16 Robust organic growth driven by all regi
Slide 9: Cash Flow Development Influenced by Portfolio Changes
Cash Flow Development Influenced by Portfolio Changes Sartorius Group € in millions 9M 2015 9M 2016 in % Reported prior-year net profit include gain from Intec divestiture Underlying EBITDA 193.8 241.4 +24.6 Net operating cash flow mainly Extraordinary items -6.7 -19.8 -197.0 influenced by growt
Slide 10: Key Financial Parameters Remain at Comfortable Levels
Key Financial Parameters Remain at Comfortable Levels Key Financial Indicators Net Debt to Underlying EBITDA Sartorius Group Dec. 31, 2015 Sep. 30, 2016 600 3.03 480 2.42,4 Equity ratio in % 44.9 39.8 360 1.81,8 Net debt in millions of € 344.0 498.7 240 1.21,2 120 0.60,6 Net debt | underlying EBITDA
Slide 11: FY 2016 Sales and Earnings Guidance Confirmed
FY 2016 Sales and Earnings Guidance Confirmed FY 2016 Guidance1 Sales Revenue Growth Underlying EBITDA Margin Sartorius Group ~ 15% - 18% ~ 25% Bioprocess Solutions ~ 19% - 22% ~ 28% Lab Products & Services ~ 6% - 9% ~ 16% 1 In constant currencies Guidance includes the following non-organic growth
Slide 12: Agenda
Agenda 01 Sartorius Group: 9M 2016 Results | FY 2016 Guidance 02 Sartorius Stedim Biotech Group: 9M 2016 Results | FY 2016 Guidance 03 Questions & Answers
Slide 13: Strong Double-digit Growth in Line With Expectations
Strong Double-digit Growth in Line With Expectations Sartorius Stedim Biotech Group in millions of € unless otherwise specified 9M 2015 9M 2016 in % in % cc 1 Sales revenue 660.9 785.1 +18.8 +20.4 Order intake 694.0 806.6 +16.2 +17.8 Underlying EBITDA2 173.2 214.1 +23.6 Underlying EBITDA2 margin 26.
Slide 14: Considerable Sales Growth in All Regions
Considerable Sales Growth in All Regions Americas EMEA Asia | Pacific Sales by Regions in € millions in € millions in € millions in % 342.7 290.2 299.5 EMEA ~ 44% 242.4 152.2 119.0 Americas ~ 37% € 785.1m 9M 15 9M 16 9M 15 9M 16 9M 15 9M 16 +21.0% +16.2% +29.8% Asia | Pacific ~ 19% Acc. to customers
Slide 15: Cash Flow Performance Influenced by Acquisitions
Cash Flow Performance Influenced by Acquisitions Sartorius Stedim Biotech Group € in millions 9M 2015 9M 2016 in % Net operating cash flow mainly influenced by growth-related Underlying EBITDA 173.2 214.1 +23.6 increase in working capital and higher tax payments Extraordinary items -2.6 -7.7 -197.
Slide 16: Financial Position Remains Strong
Financial Position Remains Strong Key Financial Indicators Net Debt to Underlying EBITDA Sartorius Stedim Biotech Dec. 31, 2015 Sep. 30, 2016 150 1.5 1,5 1.5 Equity ratio in % 60.7 60.5 120 1.2 1.2 1,2 90 0.9 0,9 0.9 Net debt in millions of € 86.4 94.6 60 0.6 0,6 0.6 30 0.3 0.3 0,3 Net debt | underl
Slide 17: FY 2016 Guidance Confirmed
FY 2016 Guidance Confirmed FY 2016 Guidance Sales revenue growth1 ~ 17% - 20% Underlying EBITDA margin1 ~ +1.5 pp vs. FY 2015: 26.2% 1 In constant currencies 1 In constant currencies Guidance includes ~ 2 pp of non-organic growth expected to be contributed by the acquisitions of BioOutsource, Cell
Slide 18: Questions & Answers
Agenda 01 Sartorius Group: 9M 2016 Results | FY 2016 Guidance 02 Sartorius Stedim Biotech Group: 9M 2016 Results | FY 2016 Guidance 03 Questions & Answers
Slide 19: Thank you very much for your attention
Thank you very much for your attention